Sanofi is restructuring its R&D group and plans to eliminate 466 jobs in France and Germany as part of a reorganization to focus on its immuno-oncology pipeline and gene therapies.   The company plans to exit cardiology research and focus on its existing assets and in-licensed clinical-phase drugs in this area. Also, the company’s diabetes research will focus on drugs that address the underlying causes of the disease but Sanofi will continue to develop its existing diabetes pipeline.   S...